Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IHL-42X in Obstructive Sleep Apnea
NCT06146101Phase 3Completed
- Sponsor
- Incannex Healthcare
- Start
- May 2024
- Primary completion
- May 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of IHL-42X in obstructive sleep apnea (OSA) (7 arms), sponsored by Incannex Healthcare. Primary endpoint: Apnea-Hypopnea Index at 4 weeks. Started May 2024; status: completed.
02
Drugs
IHL-42X
03
Conditions
obstructive sleep apnea (OSA)
Beyond the preview
Go deeper on NCT06146101.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06146101.